Boehringer Ingelheim has launched Arti-Cell Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.

Equine lameness is truly common and impacts horse performance as well as equine welfare1. Current treatment is not satisfactory for all cases and there is a clear need for innovation and new treatment options. Hence, the significant interest in treatment beyond symptoms, namely combatting the underlying root cause.

Arti-Cell Forte is claimed to be the first-ever approved therapy, developed towards targeting lameness, utilising specifically primed, chondrogenic induced stem cells. Arti-Cell Forte comes in an ultra-low frozen ready-to-use presentation.

Boehringer Ingelheim and Global Stem cell Technology (GST), that formed a partnership last year, have the same ambition to bring new treatments and solutions to improve animal health; therefore, Arti-Cell Forte was specifically designed for horses to provide a convenient and long-term2 solution for recurrent lameness.

European Commission has granted marketing authorization for the first stem cell-based product in animal health developed by Boehringer Ingelheim.